Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE: 000153)
Health Care · Pharmaceuticals · CN
CN¥6.11
+0.33% today · -5.1% 1Y
Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE: 000153) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $423.27M and employs 4,278 people.
Over the last twelve months the share price has lost 5.1%, trading between 4.95 and 7.35.
Tweenvest scores Anhui Fengyuan Pharmaceutical Co., Ltd. across four factors: quality 66/100, value 30/100, growth 18/100, dividend 38/100. Its strongest factor is quality.
000153 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $423.27M
- Revenue (TTM)
- $515.61M
- P/E
- 30.07
- EPS
- 0.20
- Dividend yield
- 1.64%
- Beta (5Y)
- 0.43
- 52-week high
- CN¥7.35
- 52-week low
- CN¥4.95
- Avg volume (3M)
- —
- Shares outstanding
- 464.69M
- Employees
- 4,278
- Next earnings
- —
About Anhui Fengyuan Pharmaceutical Co., Ltd.
Established in Hefei, China in 1997, Anhui Fengyuan Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of a wide array of medicinal products. The company primarily serves the Chinese market, offering biological pharmaceuticals, chemical drugs, and traditional Chinese medicines. Its extensive product portfolio addresses numerous health concerns, including pain and fever relief, cardiovascular conditions, infections, neurological disorders, cancer, ulcers, and hormonal imbalances. Fengyuan Pharmaceutical also produces nutritional supplements, treatments for vitamin and mineral deficiencies, anti-parasitic and antimicrobial agents, coenzymes, antiviral medications, and uterine contractants. Furthermore, its offerings encompass sedative-hypnotics, drugs for irritable bowel syndrome, hypertension treatments, and remedies for benign prostatic hyperplasia. Beyond its domestic operations, the company exports its pharmaceutical goods to international markets such as Europe, North America, Africa, Southeast Asia, and Central Asia.
- ISIN
- CNE0000014X5
- Founded
- 1997
- Listed since
- Sep 20, 2000
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AgomAb Therapeutics NVNasdaqGS: AGMB | $433.38M | $8.80 | -0.45% |
| Shaanxi Panlong Pharmaceutical Group Co., Ltd.SZSE: 002864 | $432.06M | CN¥21.05 | +0.48% |
| Nika Pharmaceuticals, Inc.OTCPK: NIKA | $431.19M | $— | — |
| Guizhou Yibai Pharmaceutical Co., Ltd.SHSE: 600594 | $425.65M | CN¥3.64 | +0.83% |
| Renata PLCDSE: RENATA | $418.17M | Tk448.70 | -0.09% |
| Chengdu huasun technology group Inc. , LTD.SZSE: 000790 | $410.99M | CN¥4.42 | -5.56% |
| Zhejiang East Asia Pharmaceutical Co., Ltd.SHSE: 605177 | $407.06M | CN¥24.26 | -6.19% |
| Atea Pharmaceuticals, Inc.NasdaqGS: AVIR | $401.83M | $5.01 | -1.18% |
Figures last refreshed Oct 4, 2026.